Updates
Sub: A small correction in the profile of the Chief Financial Officer of the Company sent to the Exchanges on May 26, 2017 along with the Outcome of the Board Meeting held on May 26, 2017 Please note that while submitting the profile of the Chief Financial Officer of the Company who is joining our Company with effect from 19th June,17 in Annexure III to the letter for the outcome of the board meeting held on May 26, 2017, there was an... Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Vrundavandas Valia L&T;, Sun Pharma most active in value terms
Most active stocks in terms of value help investors to identify the stocks with highest trading turnover during the day. Muted fourth quarter earnings drag down Sun Pharma
Shares of Sun Pharma were down over 10 per cent today, following weak fourth quarter earnings. Consolidated net profit of Sun Pharmaceutical Industries - the country's largest drug maker - fell 14... India's Biggest Drugmaker's Shares Plunge 13%. Should You Buy?
Sun Pharma has been working on fixing problems at its Halol plant in India, where the US Food and Drug Administration has raised concerns about quality control violations. Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha S Valia Significant price erosion in US takes toll on Sun Pharma
After the disappointment by Taro (Sun Pharma's US subsidiary) earlier this week, the stage was set for a weak show by Sun Pharma in the March 2017 quarter (Q4). With premium pricing of products, Taro had so far driven US sales and margins of Sun Pharma, which faces delayed product approvals and launches on the back of the Warning letter issues by the US FDA to its Halol plant. With Taro's portfolio, primarily dermatology, under pricing pressure, Sun was bound to see pressure in US sales. However, Sun's results were way below expectations and hence, after Monday's cut due to Taro (Kotak Institutional Equities had cut FY18/19 estimates by three per cent each) analysts could further cut their earnings estimate.Taro contributes more than half to Sun's US sales, and saw revenues decline 26 per cent year-on-year in Q4; fall in operating and net profit was steeper at 44 per cent and 28 per cent. Sun's US sales at $381 million, thus fell by 34 per cent. Excluding Taro, the pressure on US... Board recommends Dividend
Sun Pharmaceutical Industries Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 26, 2017, inter alia, has recommended payment of dividend of Rs. 3.5/- (Rupees Three and Fifty Paise Only) per equity share of Re. 1/- each of the Company for the year ended March 31, 2017, subject to the approval of the members at the ensuing Annual General Meeting of the Company.The dividend is expected to be paid on or about last week of September, 2017. Financial Result For Fourth Quarter & Full Year FY17.
Please find enclosed herewith our Press Release relating to fourth quarter & full year FY17 financials, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, Yours faithfully, For Sun Pharmaceutical Industries Ltd Financial Results For March 31, 2017 And Outcome Of Board Meeting Held Today.
1.The Board of Directors of the Company at its meeting held today approved and took on record the Financial Results for Fourth Quarter and Annual Audited Standalone and Consolidated Financial Results for the year ended March 31, 2017. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following as Annexure I:...